Skoči na glavni sadržaj

Izvorni znanstveni članak

Pseudocholinesterase activity in cerebrospinal fluid as a biomarker of solid central nervous system tumors in children

Lili Mikecin ; University Clinical Center Maribor Pediatric Intensive Care Unit, Maribor, Slovenia
Miljenko Križmarić ; Faculty of Medicine University of Maribor;, Faculty of Health Sciences University of Maribor, Maribor, Slovenia
Jasminka Stepan Giljević ; Department of Hematology and Oncology, Children’s Hospital Zagreb, Zagreb, Croatia
Miroslav Gjurašin ; Department of Neurosurgery Children’s Hospital Zagreb, Zagreb, Croatia
Josipa Kern ; Department of Medical Statistics, Epidemiology and Medical Informatics, School of Public Health Andrija Štampar, University of Zagreb Medical School, Zagreb, Croatia
Jasna Leniček Krleža ; Department for Clinical Chemistry Children’s Hospital Zagreb, Zagreb, Croatia
Ljiljana Popović

Puni tekst: engleski pdf 288 Kb

str. 429-435

preuzimanja: 451



Aim To determine the activity of pseudocholinesterase
(PChE) in cerebrospinal fluid (CSF) and serum in children
with solid central nervous system (CNS) tumor and to assess
whether PChE activity could be a valid biomarker for
solid CNS tumors in children.
Methods The study and control group included 30 children
each. Children in the study group had a solid CNS tumor,
while those from the control group had never suffered
from any tumor diseases. CSF and serum samples were collected
from all participants and PChE activity was determined
using the Ellman’s spectrophotometric method.
PChE activity in CSF was shown as a cerebrospinal fluid/serum
ratio expressed in percentage, ie, PChE CSF/serum ratio.
Receiver operating characteristic (ROC) curve was used
to assess whether PChE activity can be used as a biomarker
for identifying children with solid CNS tumors.
Results Children with solid CNS tumor had significantly
higher PChE activity in CSF and serum, as well as PChE
CSF/serum ratio (P = 0.001). PChE CSF/serum ratio in the
study group was 2.38% (interquartile range [IQR] 1.14-3.97)
and 1.09% (IQR 0.95-1.45) in the control group. ROC curve
analysis of PChE CSF/serum ratio resulted in an area under
the curve (AUC) value of 0.76 (95% confidence interval [CI]
0.63-0.88) and a cut-off of 1.09. Twenty five of 29 patients
with elevated PChE CSF/serum ratio had a tumor, corresponding
to a sensitivity of 83% and a specificity of 53%.
Conclusion PChE CSF/serum ratio may be used as a test
or biomarker with good sensitivity for solid CNS tumors in

Ključne riječi

Hrčak ID:



Posjeta: 800 *